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Abstract 
BACKGROUND: The failure of mucus clearance in bronchiectasis can be improved by chest physiotherapy 
or/and mucoactive agents. 
AIM: To assess the effects of long-term use of carbocysteine on frequency and duration of exacerbations in 
patients with bronchiectasis. 
METHODS: We performed an observational, non-randomized, open study (a real-life study) including 64 patients 
with bronchiectasis divided into two groups, examined group (EG) and control group (CG). All participants were 
treated with appropriate treatment for the stable disease, but in the study, subjects of EG two capsules 375 mg 
carbocysteine three times a day was added over three months. Daily diary cards realised collection of data 
regarding the occurrence and duration of exacerbation in all study subjects. 
RESULTS: Over the study period 43 exacerbations were documented, 17 in the EG and 26 in the CG, 10 (23.4%) 
of which required hospital treatment (four in the EG [23.5%] and six in the CG [23.1%]). A mean number of 
exacerbations over the study period was significantly lower in the EG (0.5 ± 0.1) as compared to their mean 
number in the CG (0.8 ± 0.2) (P = 0.0000). Mean duration of exacerbations expressed in days needed for 
complete resolution of symptoms or return of the symptoms to their baseline severity in the EG was significantly 
shorter than the mean duration of exacerbations in the CG (10.1 ± 2.6 vs 12.8 ± 2.1; P = 0.0000). The frequency 
of adverse effects, i.e. mild gastrointestinal manifestations and headache which did not require discontinuation of 
the treatment, in the EG during the study period was 15.6%. 
CONCLUSION: Our findings indicated positive effects of carbocysteine regarding the frequency and duration of 
exacerbations, as well as its good tolerability in the patients with bronchiectasis. 
 
Introduction 
 
Bronchiectasis is a heterogeneous disease 
with highly variable impact to patients (varying from 
patients without daily symptoms and infrequent 
exacerbations to patients requiring lung 
transplantation), so the treatment should be 
appropriate to stage and severity of disease in a 
certain patient. On the other side, so far, the treatment 
of bronchiectasis is not strongly supported by clinical 
trial evidence, and clinical practice guidelines have 
largely been formulated through consensus in expert 
opinion.  
As main goals of the treatment of 
bronchiectasis, i.e. the treatment of stable disease 
and the treatment of exacerbation, are considered: to 
improve airway mucus clearance through 
physiotherapy with or without adjunctive therapies; to 
suppress, eradicate and prevent airway bacterial 
colonisation; to reduce airway inflammation; to 
prevent exacerbations; and to improve physical 
functioning and quality of life [1], [2]. 
Improving airway clearance is considered as 
one of the cornerstones of the bronchiectasis 
treatment. The failure of mucus clearance can be 
improved by chest physiotherapy (breathing 
techniques, postural drainage, instrumental 
techniques, etc.) and mucoactive agents (hypertonic 
saline, dry mannitol powder, cysteine derivates, etc.). 
Treatment choice should be influenced by clinical 
experience, as by research, reflecting the limited 
evidence in this domain, as well as by patient’s status 
and preference [3], [4], [5]. 
Mucoactive agents can be used for both 
management of stable disease and exacerbations. 
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Available as oral, inhaled, or nebulised agents, they 
reduce sputum viscosity and aid expectoration, 
thereby theoretically shorten exacerbation frequency 
and length and improve symptoms and quality of life 
[6]. 
According to the European Bronchiectasis 
Guidelines and the European Respiratory Society 
guidelines for the management of adult 
bronchiectasis, a long-term mucoactive treatment, i.e. 
use of cysteine derivates, hypertonic saline, mannitol 
or isotonic saline three months or more, is suggested 
in patients who have difficulties in expectorating 
sputum and poor quality of life and where standard 
airway clearance techniques have failed to control 
symptoms [7], [8]. Similarly, according to the Spanish 
Guidelines on Treatment of Bronchiectasis in Adults, a 
long-term mucoactive treatment, i.e. use of mucolytics 
or hypertonic substances may improve sputum 
purulence a lung function and reduce exacerbation 
frequency [9]. Also, the British Guidelines for the 
Management of Bronchiectasis in Primary Care 
recommended a long term mucoactive treatment, i.e. 
nebulised hypertonic saline or carbocysteine for 6 
months in patients with excessive viscous mucus. The 
dosage of carbocysteine should be two 375 mg 
capsules three times a day, and the treatment should 
be stopped if no benefit [10]. According to the recent 
Australian recommendations for treatment of 
bronchiectasis in adults, mucoactive agents should be 
used by patients with substantial sputum burden, 
difficulty expectorating sputum, poor quality of life 
and/or frequent exacerbations despite standard 
airway clearance techniques [11]. Carbocysteine, i.e. 
S-Carboxymethyl-L-cysteine, is a mucolytic that 
reduces the viscosity of sputum, allowing its easily 
bringing up. As a mucolytic, it is used for some time in 
respiratory diseases characterised by hypersecretion 
of viscose mucus, such as acute bronchitis, chronic 
bronchitis, COPD and bronchiectasis [12]. Due to the 
antioxidant properties of carbocysteine and other 
mucolytics (i.e. free radicals scavenging and anti-
inflammatory effects), several studies indicated their 
immunomodulatory and anti-inflammatory effects [13]. 
The present study aimed to assess the effects 
of long-term use of carbocysteine on incidence and 
duration of exacerbations in patients with 
bronchiectasis. This study is a continuum of our 
investigating the effects of carbocysteine in the 
treatment of lung diseases characterised by excessive 
production of viscous mucus [14], [15]. 
 
 
Methods 
 
Study design and setting 
An observational, non-randomized, open-label 
study (a real life-study) was realised as a comparison 
of frequency and duration of exacerbations between a 
group of patients with bronchiectasis who received 
carbocysteine over three months and a group of 
patients with bronchiectasis who did not receive 
carbocysteine in the same period. The study was 
performed in the period February-December 2019 at 
the Institute for Occupational Health of R. North 
Macedonia, Skopje. 
 
Study subjects 
The study population included 64 subjects 
with bronchiectasis who had to have difficulties in 
expectorating sputum and poor quality of life and who 
was not able to perform standard airway clearance 
techniques, or these techniques failed to control 
symptoms of the disease. The study subjects were 
divided into two groups similar by their characteristics: 
examined group (EG) and control group (CG). 
EG included 32 patients with bronchiectasis, 
18 males and 14 females, aged 46 to 76 years. The 
study subjects from EG besides the appropriate 
treatment of stable disease were treated with two 375 
mg capsules carbocysteine three times a day over 
three months in which number and duration of 
exacerbations were registered. 
Also, an equal number of patients with 
bronchiectasis (19 males and 13 females, aged 47 to 
74 years) with similar characteristics as those from 
EG were treated only with the appropriate treatment of 
stable disease and followed over three months. 
All participants were informed about the 
study, and their written consent was obtained. 
 
Demographic and other characteristics of 
 the study subjects 
Demographics of the study subjects, including 
sex, age, smoking status, body mass index (BMI), 
previous or current occupational exposure to noxious 
particles and gases, and comorbidities were collected 
by questionnaire at the initial visit. 
Classification of the smoking status of the 
study subjects was done by the World Health 
Organization (WHO) recommendations [16]. Passive 
smoking or exposure to environmental tobacco smoke 
was defined as exposure to tobacco combustion 
products from smoking by others (at home, workplace, 
etc.), i.e. as a presence of at least one smoker in the 
household and/or in the workplace [17]. 
The Body Mass Index (BMI) as a measure of 
body fat based on height and weight that applies to 
adult population was determined in all study subjects 
by computed calculation using BMI calculator [18]. 
Daily stable respiratory symptoms, medication 
use and history of exacerbations in the last 12 months 
were noted in all subjects before entering the study. 
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All study subjects underwent baseline and post-
bronchodilator spirometry according to the actual 
recommendations [19]. Also, microbiological 
evaluation of sputum was performed in all study 
subjects in the stable phase of the disease, as well as 
when the exacerbation was diagnosed [20]. 
 
Diagnosis and assessment of 
 bronchiectasis 
Diagnosis of bronchiectasis was based on the 
findings of high resolution computed tomography 
(HRCT) as it is currently considered as the best tool 
for its diagnostics [21], [22]. Patients with diagnosed 
bronchiectasis underwent a range of investigations to 
determine the underlying cause, as well as to 
determine the severity of the disease [23]. Diagnosis 
and assessment of COPD were made following the 
actual recommendations of the Global Initiative for 
COPD (GOLD) [24]. Following the recommendation of 
the Bronchiectasis Severity Index (BSI), 
bronchiectasis was classified as mild, moderate and 
severe [25]. 
 
Diagnosis and treatment of BE 
 exacerbation 
BE exacerbations were diagnosed according 
to the criteria from the actual guidelines mentioned 
above [26]. The antibiotic therapy lasted 14 days 
being etiological or empirical depending on the results 
of sputum culture [27], [28]. The course of 
exacerbation was evaluated as a function of the 
resolution of symptoms, and the treatment was 
considered to be successful if cure or clinical 
improvement, i.e. return of the symptoms to their 
baseline severity, was achieved. 
 
Data collection (Daily diary card) 
Collection of data regarding the occurrence 
and duration of exacerbation in all study subjects was 
realised by daily diary cards following the model used 
by Patel et al., (2004) in the study on bronchiectasis 
and exacerbation indices [29]. The mentioned model 
was used and explained in our previous studies on 
exacerbations in COPD patients with bronchiectasis 
[30]. 
 
Statistical analysis 
Statistical analysis was performed using the 
Statistical Package for the Social Sciences (SPSS) 
version 11.0 for Windows. Continuous variables were 
expressed as mean values with standard deviation 
(SD), and the nominal variables as numbers and 
percentages. Analyses of the data included testing the 
differences in prevalence and comparison of the 
means by chi-square test (or Fisher’s exact test where 
appropriate) and independent-samples T-test. A P-
value of less than 0.05 was considered as statistically 
significant. 
 
 
Results 
 
Demographic and other characteristics of the 
study subjects are shown in Table 1. In both groups, 
there was not any patient receiving long-term 
treatment with systemic or inhaled antibiotics. Patients 
with accompanied COPD (about one third in both 
groups) were treated according to the actual GOLD 
recommendations [24]. 
Table 1: Characteristics of the study subjects 
Variable 
EG 
(n = 32) 
CG 
(n = 32) 
M/F ratio 
Mean age (years) 
Mean BMI (kg/m
2
) 
Smoking status 
Never smokers 
Active smokers 
Ex-smokers Exposed to ETS 
1.3 
54.3  7.8 
25.6  2.8 
9 (28.0%) 
14 (43.7%) 
9 (28.0%) 
15 (46.8%) 
1.4 
53.9  8.4 
25.3  3.7 
10 (31.2%) 
13 (40.6%) 
9 (28.0%) 
13 (40.6%) 
Mean duration of disease after diagnosis (years) 
Classification of disease severity  
by the BSI score  
Mild 
Moderate 
Severe  
Mean values of spirometric parameters (% pred.) 
FVC 
FEV1 
FEV1/FVC ratio 
Positive sputum culture when clinically stable over the last 12 
months  
Haemophilus influenzae 
Moraxella catarrhal 
Streptococcus pneumoniae 
Pseudomonas aeroginosa 
Serratia marscences 
Staphylococcus aureus 
Other 
No bacteria isolated 
Accompanied COPD 
8.6  3.4 
 
 
12 (37.5%) 
14 (43.3%) 
6 (18.7%) 
 
74.6  6.1 
52.3  4.8 
0.70  0.04 
 
 
10 (31.2%) 
4 (12.5%) 
3 (9.4%) 
3 (9.4%) 
2 (6.2%) 
1 (3.1%) 
2 (6.2%) 
7 (21.8%) 
10 (31.2%) 
9.0  3.9 
 
 
13 (41.9%) 
13 (41.9%) 
6 (18.7%) 
 
76.1  7.2 
56.1  4.3 
0.70  0.07 
 
 
11 (34.4%) 
5 (15.6%) 
3 (9.4%) 
2 (6.2%) 
3 (9.4%) 
1 (3.1%) 
2 (6.2%) 
5 (15.6%) 
9 (28.0%) 
Mean number of exacerbations in the last 12 months 2.7  0.4 2.6  0.5 
Numerical data are expressed as mean value with standard deviation; frequencies as number and 
percentage of study subjects with certain variable; EG: examined group; CG: control group; M: male; F: 
female; BMI: body mass index; kg: kilogram; m: meter; ETS: environmental tobacco smoke; BSI: 
Bronchiectasis Severity Index; % pred.: % of the predicted value; FVC: forced vital capacity; FEV1: forced 
expiratory volume in one second; COPD: chronic obstructive pulmonary disease. 
  
Over the study period 43 exacerbations were 
documented (17 in the EG and 26 in the CG), 10 
(23.4%) of which required hospital treatment (four in 
the EG [23.5%] and six in the CG [23.1%]).  
A mean number of exacerbations over the 
study period was significantly lower in the EG (0.5 ± 
0.1) as compared to their mean number in the CG (0.8 
± 0.2) (P = 0.0000) (Figure 2). 
 
Figure 1: Mean number of exacerbations in the study subjects over 
a three-month period 
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Positive sputum culture was obtained in 34 
exacerbations (14 in the EG and 20 in the CG) (Table 
2). 
Table 2: Findings of sputum culture in exacerbations 
Sputum culture 
EG 
(n = 17) 
CG 
(n = 26) 
Haemophilus influenzae 
Moraxella catarhalis 
Streptococcus pneumoniae 
Pseudomonas aeroginosa 
Other 
No bacteria isolated 
7 (41.1%) 
2 (11.8%) 
2 (11.8%) 
1 (5.9%) 
2 (11.8%) 
3 (17.6%) 
9 (34.6%) 
3 (11.5%) 
3 (11.5%) 
2 (7.7%) 
3 (11.5%) 
6 (23.1%) 
 
Majority of exacerbations (33 of 43 
exacerbations [76.7%]) were treated with systemic 
antibiotics (12/17 [70.6%] in the EG and 21/26 [73.1%] 
in the CG. Also, 10 exacerbations (23.3%) were 
treated with systemic antibiotics and systemic 
corticosteroids. 
Mean duration of exacerbations expressed in 
days needed for complete resolution of symptoms or 
return of the symptoms to their baseline severity in the 
EG was significantly shorter than the mean duration of 
exacerbations in the CG (10.1 ± 2.6 vs 12.8 ± 2.1; P = 
0.0000) (Figure 2). 
 
Figure 2: Mean duration of exacerbations in the study subjects 
 
The frequency of adverse effects in EG during 
the study period was 15.6%. Mild and self-limited 
gastrointestinal manifestations (epigastric pain, 
nausea, vomiting, and diarrhoea) and headache, 
which did not require discontinuation of the treatment 
were registered in five patients (Figure 3). 
 
Figure 3: Adverse effects registered in the EG 
Discussion 
 
Impaired mucociliary clearance and mucus 
retention contribute to the chronic cycle of airway 
inflammation, infection and damage in bronchiectasis 
[31], [32]. There is a strong rationale for the use of 
pharmacological strategies to aid airway clearance, 
often in combination with chest physiotherapy. On the 
other side, despite the availability of many candidate 
mucoactive agents for many years, the evidence base 
for recommending these agents is still limited [33]. 
Carbocysteine (S-Carboxymethylcysteine – S-
CMC), although commonly regarded as a mucolytic, 
has a mechanism of action that differs from that of 
classical mucolytics (e.g. N-Acetylcysteine). Mucus 
produced under the action of carbocysteine shows an 
increase in sialomucin content. Sialomucins, which 
are structural components of mucus, influence the 
viscoelastic properties of mucus. Carbocysteine, also 
exerts anti-inflammatory action decreasing levels of 
the cytokines interleukin-6 (IL-6) and interleukin-8 (IL-
8) and reducing neutrophil influx into the airway lumen 
[34], [35]. 
Aim of the present study was to assess the 
effect of long-term use of carbocysteine on frequency 
and duration of exacerbations in patients with 
bronchiectasis. According to the actual 
recommendations, the study population included 
patients with bronchiectasis who had to have 
difficulties in expectorating sputum and poor quality of 
life and who was not able to perform standard airway 
clearance techniques, or these techniques failed to 
control symptoms of the disease. The study subjects 
were divided into two groups with similar 
characteristics regarding the treatment with 
carbocysteine besides the appropriate treatment of 
stable disease. In both groups there was a large 
proportion of active and passive smokers, as well as a 
low proportion of ex-smokers, that was similar to their 
prevalence in general population documented in our 
previous studies [36], [37]. These findings suggest 
insufficient anti-smoking activities, i.e. they indicate a 
need for improvement of the control of tobacco use in 
R. Macedonia. According to the results of studies on 
smoking status conducted in developed countries, e.g. 
New Jersey Adult Tobacco Survey and Australian 
National Health Survey, in the countries with more 
effective anti-smoking strategies, there is a 
significantly lower prevalence of active and passive 
smokers and significantly higher prevalence of ex-
smokers as compared to their prevalence registered 
in our studies [38], [39]. Results of the present study 
indicated lower frequency and lower duration of 
exacerbations in the group who received 
carbocysteine over three months as compared to 
exacerbations frequency and duration in the group 
who did not receive carbocysteine. The majority of 
clinical studies of cysteine derivates have been 
performed in COPD, with conflicting results [15], [40], 
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[41]. The evidence supporting the use of cysteine 
derivates in bronchiectasis is even more limited. 
Results from the study conducted by Yi-Fong 
Su et al., in Taiwan which included 831 patients with 
bronchiectasis-chronic obstructive pulmonary disease 
overlap (BCO) indicated that a long term use (more 
than 90 days) of carbocysteine os associated with 
significantly lower risk of exacerbations. Similar 
results were obtained for a long-term use of N-
acetylcysteine, ambroxol, and bromhexine, but not for 
iodinated glycerol [42]. Over the treatment mild 
gastrointestinal effects and headache occurred in 
about 15% of the study subjects who received 
carbocysteine. Nausea, stomach upset, diarrhea, and 
headache are considered as common side effects of 
carbocysteine which do not require discontinuation of 
the treatment. In addition, during the use of 
carbocysteine may occur severe side effects including 
severe allergic reactions, symptoms of low blood 
sugar (dizziness, drowsiness, weakness, fainting, 
tremor, etc), and bleeding from gastrointestinal tract 
(blood in vomit or black stools). These side effects 
occur rarely, affecting less than 1 in 1,000 people [43], 
[44]. The findings of this study should be interpreted 
within the context of its limitations. First, the study 
design, i.e. neither blinded nor randomized, could 
have certain implications on data obtained and its 
interpretation. Second, relatively small number of the 
study subjects also could have certain implications on 
data obtained and its interpretation. On the other 
hand, the study design may be its strength, as it is 
documented by other real life-studies. In addition, the 
study results could improve the limited knowledge 
about the role of carbocysteine in the treatment of 
stable bronchiectasis. 
In conclusion, in an observational, non-
randomized, open-label study aimed at assessment of 
effects of a long-term use of carbocysteine on 
frequency and duration of exacerbations in patients 
with bronchiectasis we found significantly lower 
frequency and duration of exacerbations in patients 
treated with carbocysteine over three months as 
compared to their frequency and duration in patients 
not treated with carbocysteine. Our findings also 
indicate a need for further studies in this domain to 
obtain more effective management of bronchiectasis. 
 
Ethical Approval 
The Ethical Committee of the Institute of 
Occupational Health of R. North Macedonia, Skopje 
approved for performing the study and publishing the 
results obtained (03-0302-572/1-12.09.2019). 
 
 
Authors Participations 
JM participated in the study design, data 
collection, managing the analyses of the study, and 
writing all versions of the manuscript. JKB and TP 
participated in the study design, managing the 
analyses of the study, as well as writing all versions of 
the manuscript. KV performed the statistical analysis 
and participated in the managing of the analyses of 
the study. SS and DM participated in the data 
collection and the managing of the analyses of the 
study. All authors read and approved the final 
manuscript. 
  
 
References 
 
1. Chalmers JD, Aliberti S, Blasi F, et al. Management of 
bronchiectasis in adults. Eur Respir J. 2015; 45:1446-1462. 
https://doi.org/10.1183/09031936.00119114 PMid:25792635 
2. O'Donnell AE. Bronchectasis. Chest. 2008; 134:816-823. 
https://doi.org/10.1378/chest.08-0776 PMid:18842914  
3. Flude IJ, Agent P, Bilton D. Chest physiotherapy techniques in 
bronchiectasis. Chest Med. 2012; 33:351-361. 
https://doi.org/10.1016/j.ccm.2012.02.009 PMid:22640850  
4. Ong HK, Lee AL, Hill CJ, et al. Effects of pulmonary 
rehabilitation in bronchiectasis: a retrospective study. Chron Respir 
Dis. 2011; 8:21-30. https://doi.org/10.1177/1479972310391282 
PMid:21339371 
 
5. Bilton D, Tino G, Barker AF, et al. Inhaled mannitol for non-cystic 
fibrosis bronchiectasis: a randomized, controlled trial. Thorax. 
2014; 69:1073-1079. https://doi.org/10.1136/thoraxjnl-2014-205587 
PMid:25246664 
 
6. Wilkinson M, Sugumar K, Milan SJ, et al. Mucolytics for 
bronchiectasis. Cochrane Database Syst Rev. 2017; 5:CD001289.  
7. Polverino E. The European Bronchiectasis Guidelines, 2019. 
Available at: www.lung-health.org (accessed 12.08.2019).  
8. Polverino E, Goeminne PC, McDonnell M, et al. European 
Respiratory Society guidelines for the management of adult 
bronchiectasis. Eur Respir J. 2017; 50:1700629. 
https://doi.org/10.1183/13993003.00629-2017 PMid:28889110 
 
9. Martinez-Garcia MA, Maiz L, Olveira C, et al. Spanish 
Guidelines on Treatment of Bronchiectasis in Adults. Arch 
Bronconeumolog. 2018; 54(2):88-98. 
https://doi.org/10.1016/j.arbr.2017.07.014 
 
10. Guidelines for the Management of Bronchiectasis in Primary 
Care, 2019. Available at: https://www.brit-thoracic.org.uk (accessed 
12.08.2019).  
11. Visser SK, Bye P, Morgan L. Management of bronchiectasis in 
adults, 2019. Available at: https://www.mja.com.au/podcasts 
(accessed 12.08.2019).  
12. Carbocisteine, 2019. Available at: www.mhra.gov.uk (accessed 
24.08.2019).  
13. van Overveld FJ, Demkow U, Gorecka D, et al. New 
developments in the treatment of COPD: comparing the effects of 
inhaled corticosteroids and N-acetylcysteine. J Physiol Pharmacol. 
2005; 56:135-142. 
 
14. Minov J, Karadzinska-Bislimovska J, Stoleski S, et al. 
Karbocistein vo ambulantsko lekuvanje na egzacerbaciite na 
hronicniot bronchitis I hronicnata opstruktivna belodrobna bolest 
[Carbocysteine in the outpatient treatment of exacerbation of 
chronic bronchitis and chronic obstructive pulmonary disease, in 
Macedonian]. Vox Medici. 2015; 86:387-391. 
 
15. Minov J, Karadzinska-Bislimovska J, Petrova T, et al. 
Carbocysteine in the Management of Stable COPD: Are Its 
Antioxidant and Anti-Inflammatory Properties Clinically Relevant? 
SEE J Immunol. 2017; 2017:2011. 
 
Minov et al. Effects of a Long-Term Use of Carbocysteine on Frequency and Duration of Exacerbations in Patients with Bronchiectasis 
_______________________________________________________________________________________________________________________________ 
_______________________________________________________________________________________________________________________________ 
Open Access Maced J Med Sci. 2019 Dec 15; 7(23):4030-4035.                                                                                                                                                 4035 
 
https://doi.org/10.3889/seejim.2017.20011 
16. World Health Organization. Guidelines for controlling and 
monitoring the tobacco epidemic. World Health Organization; 1998.  
17. US Department of Health and Human Services. The health 
consequences of smoking: chronic obstructive pulmonary disease. 
A report of the Surgeon General. US Department of Health and 
Human Services. Public Health Service, Office of the Assistant for 
Health, Office of Smoking and Health. DHHS Publication. 1984(84-
50):205. 
 
18. Calculate your Body Mass Index, 2019. Available at: 
https://www.nhlbi.nih.gov (Accessed: 16.08.2019).  
19. Spirometry Guide: 2010 Update, 2010. Available at: 
http://www.goldcopd.org/uploads/users/files/GOLD_Spirometry_20
10. (Accessed: 16.08.2019).  
20. Barrow GI, Feltham RKA. Cowan and Steel's manual for 
identification of medical bacteria. 3rd ed. Cambridge: Cambridge 
University Press, 2004.  
21. Pasteur MC, Bilton D, Hill AT, et al. British Thoracic Society 
guideline for non-CF bronchiectasis. Thorax. 2010; 65(1):i1-i58. 
https://doi.org/10.1136/thx.2010.136119 PMid:20627931  
22. McGuinness G, Naidich DP. CT of airways disease and 
bronchiectasis. Radiol Clin North Am. 2002; 40:1-19. 
https://doi.org/10.1016/S0033-8389(03)00105-2  
23. Drain M, Elborn JS. Assessment and investigations in adult 
with bronchiectasis. Eur Respir Mon. 2011; 52:32-43. 
https://doi.org/10.1183/1025448x.10003410  
24. Global Strategy for the Diagnosis, Management, and 
Prevention of Chronic Obstructive Pulmonary Disease. 2019. 
Available at: htpps://goldcopd.org/ (Accessed 20.08.2019).  
25. Chalmers JD, Goeminne P, Aliberti S, et al. The Bronchiectasis 
Severity Index. An Interantional Derivation and Validation Study. 
Am j Respir Crit Care Med. 2014; 189(5):576-585. 
https://doi.org/10.1164/rccm.201309-1575OC PMid:24328736 
PMCid:PMC3977711 
 
26. Hill TA, Haworth CS, Aliberti S, et al. Pulmonary exacerbation 
in adults with bronchiectasis: a consensus definition for clinical 
research. Eur Respir J. 2017; 49:1700051. 
https://doi.org/10.1183/13993003.00051-2017 PMid:28596426 
 
27. Identifying an exacerbation, 2019. Available at: 
http://bronchiectasis.com.au/(Accessed 20.08.2019).  
28. Bronchiectasis antibiotic guidelines, 2019. Available at: 
https://www.gloshospitals.nhs.uk/ (Accessed 20.08.2019).  
29. Patel IS, Vlahos I, Wilkinson TMA, et al. Bronchiectasis, 
Inflammatory indices, and Inflammation in Chronic Obstructive 
Pulmonary Disease. Am J Respir Crit Care Med. 2004; 170:400-
407. https://doi.org/10.1164/rccm.200305-648OC PMid:15130905 
 
30. Minov J, Stoleski S, Mijakoski D, et al. Exacerbations in COPD 
patients with bronchiectasis. Med Sci. 2017; 5(2):7. 
https://doi.org/10.3390/medsci5020007 PMid:29099023 
PMCid:PMC5635786 
 
31. Cole PJ. Inflammation: a two-edged sword - the model of 
bronchirctasis. Eur J Respir Dis. 1986; 147:6-15.  
32. King PT. The pathophysiology of bronchiectasis. Int J COPD. 
2009; 4:411-419. https://doi.org/10.2147/COPD.S6133  
PMid:20037680 PMCid:PMC2793069 
33. Bye PT, Lau EMT, Elkins MR. Pharmacological airway 
clearance strategies in bronchiectasis. Available at: 
www.sppneumologia.pt (Accessed 15.08.2019).  
34. Hooper C, Calvert J. The role for S-carboxymethylcysteine 
(carbocysteine) in the management of chronic obstructive 
pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2008; 3:659-
669. https://doi.org/10.2147/COPD.S3735 PMid:19281081 
PMCid:PMC2650606 
 
35. Carpagnano CE, Resta O, Foschino-Barbaro MP, et al. Inhaled 
interleukine-6 and isoprostane-8 in chronic obstructive pulmonary 
disease: effect of carbocysteine lysine salt monohydrate (SCMC-
lys). Eur J Pharmacol. 2004; 505:169-175. 
https://doi.org/10.1016/j.ejphar.2004.10.007 PMid:15556150 
 
36. Minov J, Karadzinska-Bislimovska J, Nelovska Z, et al. 
Smoking among Macedonian workers five years after anti-smoking 
campaign. Arh Hig Rada Toksikol. 2012; 63:207-213. 
https://doi.org/10.2478/10004-1254-63-2012-2150 PMid:22728803 
 
37. Minov J. Smoking among Macedonian Workers. Saarbrücken: 
LAP LAMBERT Academic Publishing; 2013.  
38. Tobacco Surveillance Data Brief: Adult Cigarette Smoking 
Prevalence. Available at: 
http://www.state.nj.us/health/as/ctcp/documents. (Accessed 
21.08.2019). 
 
39. South Australian smoking prevalence by industry and 
occupation. Available at: www.cancersa.org.au/ (Accessed 
21.07.2019).  
40. Decramer M, Rutten-van Molken M, Dekhuijzen, et al. Effects 
of N-acetylcysteine on outcomes in chronic obstructive pulmonary 
disease (Bronchitis Randomized on NAC Cost-Utility Study, 
BRONCUS): a randomized, placebo-controlled trial. Lancet. 2005; 
365:1552-1560. https://doi.org/10.1016/S0140-6736(05)66456-2 
 
41. Zheng JP, Kang J, Huang SG, et al. Effect of carbocysteine on 
acute exacerbation of chronic obstructive pulmonary disease 
(PEACE study): a randomized, placebo-controlled study. Lancet. 
2008; 371:2013-2018. https://doi.org/10.1016/S0140-
6736(08)60869-7 
 
42. Yi-Fong Su V, Perng D-W, Chou T-C, et al. Mucolytic agents 
and statine use is associated with a lower risk of acute 
exacerbations in patients with bronchiectasis-chronic obstructive 
pulmonary disease overlap. J Clin Med. 2018; 7:517. 
https://doi.org/10.3390/jcm7120517 PMid:30518165 
PMCid:PMC6306823 
 
43. Tatsumi K, Fukuchi Y; PEACE Study Group. Carbocysteine 
improves quality of life in patients with chronic obstructive 
pulmonary disease. J Am Geriatr Soc. 2007; 55(11):1884-1886. 
https://doi.org/10.1111/j.1532-5415.2007.01373.x PMid:17979906 
 
44. Zheng Z, Yang D, Huang X, et al. Effect of carbocysteine on 
patients with COPD: systematic review and meta-analysis. Int J 
COPD. 2017; 12:2277-2283. 
https://doi.org/10.2147/COPD.S140603 PMid:28814855 
PMCid:PMC5546781 
 
 
 
